We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
European experience with the Afirma Gene Expression Classifier for indeterminate thyroid nodules: A clinical utility study in the Netherlands.
- Authors
Lončar, Ivona; van Velsen, Evert F. S.; Massolt, Elske T.; van Kemenade, Folkert J.; van Engen‐van Grunsven, Adriana C. H.; van Hemel, Bettien M.; van Nederveen, Francien H.; Netea‐Maier, Romana; Links, Thera P.; Peeters, Robin P.; van Ginhoven, Tessa M.
- Abstract
Background: The Gene Expression Classifier (GEC) and Genomic Sequencing Classifier (GSC) were developed to improve risk stratification of indeterminate nodules. Our aim was to assess the clinical utility in a European population with restrictive diagnostic workup. Methods: Clinical utility of the GEC was assessed in a prospective multicenter cohort of 68 indeterminate nodules. Diagnostic surgical rates for Bethesda III and IV nodules were compared to a historical cohort of 171 indeterminate nodules. Samples were post hoc tested with the GSC. Results: The GEC classified 26% as benign. Surgical rates between the prospective and historical cohort did not differ (72.1% vs. 76.6%). The GSC classified 59% as benign, but misclassified six malignant lesions as benign. Conclusion: Implementation of GEC in management of indeterminate nodules in a European country with restrictive diagnostic workup is currently not supported, especially in oncocytic nodules. Prospective studies with the GSC in European countries are needed to determine the clinical utility.
- Subjects
NETHERLANDS; THYROID nodules; GENE expression; NEEDLE biopsy
- Publication
Head & Neck, 2023, Vol 45, Issue 9, p2227
- ISSN
1043-3074
- Publication type
Article
- DOI
10.1002/hed.27472